BACKGROUND: New therapeutics are urgently needed to improve the outcome of men with castrate-resistant prostate cancer (mCRPC), a leading cause of cancer-related deaths in Canadian men. Prostate-specific membrane antigen (PSMA) is a known biomarker and therapeutic target for prostate cancer. Radioligand therapy (RLT) targeting PSMA has shown promising results in mCRPC, and a substantial subset of prostate cancer patients may benefit from this approach. The safety, tolerability, and anti-tumour activity of PSMA RLT in comparison to chemotherapy should be investigated prospectively to evaluate this treatment for Canadian mCRPC patients.
AIMS: (1) Harmonize production and distribution of PSMA radiopharmaceuticals for introduction into Canadian clinical trials;; and (2) Conduct a randomized Phase 2 trial to compare PSMA RLT with chemotherapy (3) Perform an economic evaluation of RLT for prostate cancer
PI: Francois Bernard